Solid Tumors Clinical Trial
Official title:
A Phase 1 Open-label, Multiple Dose, Dose Escalation Study of Monoclonal Antibody AV-203 Administered in Subjects With Metastatic or Advanced Solid Tumors
Verified date | April 2015 |
Source | AVEO Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | United States: Food and Drug Administration |
Study type | Interventional |
This is a Phase 1, multi-center, open-label, multiple dose, dose escalation study to evaluate the safety, tolerability, dose limiting toxicities (DLTs), maximum tolerated dose (MTD) and/or Recommended Phase 2 Dose (RP2D), pharmacokinetic (PK), pharmacodynamics, and preliminary anti-tumor activity of AV-203, an ERBB3 inhibitory antibody, administered once every 2 weeks via intravenous (IV) infusion in subjects with metastatic or advanced solid tumors. Once the RP2D is determined, patients with tumor types of interest will be evaluated in an expansion cohort at the RP2D for safety and anti-tumor activity.
Status | Completed |
Enrollment | 24 |
Est. completion date | December 2014 |
Est. primary completion date | December 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - = 18 years of age - Histologically and/or cytologically confirmed primary diagnosis - Metastatic or advanced solid tumor, that has recurred or progressed following standard therapies, or for which no standard therapy exists - Must have available tumor tissue or be willing to undergo biopsy prior to enrollment - Eastern Cooperative Oncology Group (ECOG) Performance status of 0 or 1 - Blood Chemistry and Hematology results within defined limits Exclusion Criteria: - History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational agent - Current central nervous system (CNS) or leptomeningeal metastases, or history of CNS or leptomeningeal metastases. - Significant conduction disturbance, history of a severe arrhythmia, or history of a familial arrhythmia - Significant cardiovascular disease - Significant thromboembolic or vascular disorders within prior 3 months - Any other medical condition or psychiatric condition that, in the opinion of the Investigator, might interfere with the subject's participation in the trial or interfere with the interpretation of trial results - Known history of positive results for hepatitis C, hepatitis B, or human immunodeficiency virus. - For female subjects, pregnancy or lactation. |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | AVEO Clinical Site | Atlanta | Georgia |
United States | AVEO Clinical Site | San Antonio | Texas |
United States | AVEO Clinical Site | Scottsdale | Arizona |
Lead Sponsor | Collaborator |
---|---|
AVEO Pharmaceuticals, Inc. |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of AEs, SAEs and Dose-limiting Toxicities (DLTs) | Ongoing throughout study. DLTs evaluated for first cycle of therapy. 1 cycle = 28 days | Yes | |
Secondary | Maximum Plasma Concentration (Cmax) of AV-203 | pre-dose, 5 min, 15 min, 7 hr, 24 hr, 168 hr post-dose | No | |
Secondary | Time to Cmax (Tmax) of AV-203 | pre-dose, 5 min, 15 min, 7 hr, 24 hr, 168 hr post-dose | No | |
Secondary | Area Under Plasma Concentration (AUC) of AV-203 | pre-dose, 5 min, 15 min, 7 hr, 24 hr, 168 hr post-dose | No | |
Secondary | Terminal phase half-life (t1/2) of AV-203 | pre-dose, 5 min, 15 min, 7 hr, 24 hr, 168 hr post-dose | No | |
Secondary | Clearance (Cl) of AV-203 | pre-dose, 5 min, 15 min, 7 hr, 24 hr, 168 hr post-dose | No | |
Secondary | Volume of Distribution (Vd) of AV-203 | pre-dose, 5 min, 15 min, 7 hr, 24 hr, 168 hr post-dose | No | |
Secondary | Objective Response Rate (ORR) | Within 28 days of first dose and every 8 weeks while on study | No | |
Secondary | Disease Control Rate (DCR) | Within 28 days of first dose and every 8 weeks while on study | No | |
Secondary | Duration of Response (DOR) | Within 28 days of first dose and every 8 weeks while on study | No | |
Secondary | Time to Progression (TTP) | Within 28 days of first dose and every 8 weeks while on study | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT00750841 -
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
|
Phase 1 | |
Withdrawn |
NCT05419817 -
Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System
|
Phase 2 | |
Completed |
NCT02828930 -
A Study to Determine the Excretion Balance, Pharmacokinetics, Metabolism and Absolute Oral Bioavailability of a Single Oral Dose of [14C]-Labeled Idasanutlin and an Intravenous Tracer Dose of [13C]-Labeled Idasanutlin in a Single Cohort of Participants With Solid Tumors (Malignancies)
|
Phase 1 | |
Completed |
NCT01197170 -
Hormone Receptor Positive Disease Across Solid Tumor Types: A Phase I Study of Single-Agent Hormone Blockade and Combination Approaches With Targeted Agents to Provide Synergy and Overcome Resistance
|
Phase 1 | |
Terminated |
NCT03225105 -
M3541 in Combination With Radiotherapy in Solid Tumors
|
Phase 1 | |
Completed |
NCT03258515 -
A Study to Investigate the Effect of Single Dose of AZD6094 (600 mg) on Cardiac Repolarization in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT01878890 -
Phase I Dose Escalation Trial of Efavirenz in Solid Tumours or Non-Hodgkin Lymphoma in Therapeutic Failure.
|
Phase 1 | |
Active, not recruiting |
NCT05059522 -
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
|
Phase 3 | |
Active, not recruiting |
NCT03634982 -
Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT04685226 -
A Phase I/II Clinical Trial of ICP-723 in the Treatment of Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 | |
Recruiting |
NCT06036121 -
A Study of ADRX-0706 in Select Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT03258151 -
Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
|
||
Completed |
NCT01528046 -
Metformin in Children With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05325866 -
A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
|
Phase 1/Phase 2 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT02759640 -
A Phase I Trial of HS-10241 in Solid Tumors
|
Phase 1 | |
Terminated |
NCT02890368 -
Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides
|
Phase 1 | |
Completed |
NCT02279433 -
A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b
|
Phase 1 |